Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
Jenna E Januszka, Emily N Drwiega, Melissa E Badowski University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USACorrespondence: Melissa E Badowski, Clinical Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago...
Main Authors: | Januszka JE, Drwiega EN, Badowski ME |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-11-01
|
Series: | HIV/AIDS: Research and Palliative Care |
Subjects: | |
Online Access: | https://www.dovepress.com/bictegraviremtricitabinetenofovir-alafenamide-for-hiv-1-what-is-the-hi-peer-reviewed-fulltext-article-HIV |
Similar Items
-
A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia
by: Kanak Parmar, et al.
Published: (2023-01-01) -
Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
by: Anna Gidari, et al.
Published: (2023-12-01) -
Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023-12-01) -
Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
by: Giuseppe Vittorio De Socio, et al.
Published: (2023-12-01) -
A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model
by: Haneesha Mohan, et al.
Published: (2022-08-01)